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A trihexacontapeptide corresponding to the sequence 8-70 of eglin c and its related peptides were synthesized by the conventional solution method 
and their inhibitory activity against human leukocyte lastase, cathepsin G and a-chymotrypsin was examined. Although synthetic eglin c (41-49) 
inhibited cathepsin G and a-chymotrypsin (K, =4.0 x 10m5 M and 2.0 x 10m5 M, respectively) but not leukocyte lastase, the synthetic trihexaconta- 
peptide potently inhibited cathepsin G, a-chymotrypsin and leukocyte elastase (K,= 1.8 x 10m9 M, 1.4 x lOe9 M and 2.2 x low9 M, respectively). 
The relationship between the stucture of eglin c and the inhibitory activity against he above enzymes is also described. 
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1. INTRODUCTION 
Eglin c, isolated from the leech Hirudo medicinalis, 
consists of 70 amino acid residues [l] and inhibits 
chymotrypsin and subtilisin as well as leukocyte elastase 
and cathepsin G. The latter two enzymes have attracted 
our interest due to their possible involvement in connec- 
tive tissue turnover and diseases uch as inflammation, 
rheumatoid arthritis and emphysema 121. Therefore, 
eglin c is a potential candidate for the therapeutic treat- 
ment of emphysema and inflammation. Rink et al. 
prepared W-acetyleglin c by means of genetic techni- 
ques [ 131, although its molecular weight is too large for 
practical therapeutic use. Previously, Bode et al. [4] and 
McPhalen and James [5] reported that the nine residues 
of the binding loop (40-48) of eglin c are involved’ in 
direct contact with subtilisin as a result of the deter- 
mination of the crystal structure of the complex formed 
between eglin c and subtilisin Carlsberg by X-ray 
analysis. It was also reported that eglin c present in the 
complex with subtilisin is shortened N-terminally by 7 
amino acid residues [4]. This observation indicates that 
eglin c derivatives hortened from the N-terminus by up 
to 7 amino acid residues should be active as an in- 
hibitor. In fact, eglin c derivatives consisting of posi- 
tions 5-70 and 7-70 which were prepared enzymatically 
using cathepsin C, exhibited the same equilibrium 
dissociation constants for the interaction of eglin c 
derivatives with chymotrypsin as that of eglin c [6]. 
This paper deals with the synthesis of a trihexacon- 
tapeptide corresponding to the sequence 8-70 of eglin c 
and its related peptides and the examination of their in- 
hibitory activity against leukocyte elastase, cathepsin G 
and cu-chymotrypsin i  order to study the relationship 
between the structure of eglin c and inhibitory activity. 
2. MATERIALS AND METHODS 
Correspondence address: Y. Okada, Faculty of Pharmaceutical 
Sciences, Kobe-Gakuin University, Nishi-ku, Kobe 651-21, Japan 
Abbreviations: Z, benzyloxycarbonyl; Boc, tert-butyloxycarbonyl; 
OBzl, benzyl ester; Mts, mesytilenesulphonyl; Born, benzylox- 
ymethyl; Sue, succinyl; pNA, p-nitroanilide 
A trihexacontapeptide was synthesized by the fragment condensa- 
tion method employing the minimal protection method. According to 
the route shown in Fig. 1, 14 peptide fragments (l-14) were prepared 
by a stepwise condensation method. A benzyl ester group on fl- or y- 
carboxyl group of Asp or Glu was removed by catalytic hydrogena- 
tion prior to use for fragment condensation. Each peptide fragment 
was condensed successively by the azide method to minimize 
racemization [7]. The protected trihexacontapeptide and related pep- 
tides were purified by reprecipitation from DMF/MeOH and/or col- 
umn chromatography on Sephadex LH-60 and their homogeneity was 
ascertained by TLC, amino acid analysis and elemental analysis. The 
final deprotection was performed by the HF method [8] using 
thioanisole and m-cresol as scavengers [9]. The product obtained as 
the HF salt was converted into an acetate form by treatment with 
Amberlite IRA 45 (acetate form) and was purified by gel-filtration on 
Sephadex G-50 using 3% AcOH as an eluant, followed by preparative 
HPLC. The homogeneity of the peptides obtained was ascertained by 
amino acid analysis and HPLC. Full details of the synthesis and 
characterization of the peptides will be published elsewhere (Y. 
Okada et al., in preparation). W-acetyleglin c was a generous gift 
from Drs. H.H. Peter and K. Scheibli of CIBA-GEIGY Ltd., Base!. 
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Fig. i. Synthetic scheme for eglin c (8-70). 
Human leukocyte lastase [lo] and cathepsin G [ll] were prepared 
in our laboratory by newly developed affinity chromatography. a- 
Ch~ot~sin was purchased from Miles Co. Ltd., Elkhart. 
Assay of leukocyte elastase, cathepsin G and ~-ch~otr~sin: En- 
zymatic activities were determined by the method described previous- 
ly [lo] using Sue-Ala-Tyr-Leu-Val-pNA [IZ] for leukocyte elastase 
and Sue-Ile-Pro-Phe;pNA [13] for cathepsin G and cr-chymotrypsin. 
Effects of synthetic peptides on the enzymes: Enzymatic activity 
was assayed in the presence or absence of the peptide examined. Ki 
values for the trihexacontapeptide were calculated according to the 
method previously described [Id] and for the other peptides according 
to the method previously described fl5]. 
3. RESULTS AND DISCUSSION 
The synthetic trihexaconta~ptide exhibited a sym- 
metrical single peak on HPLC as shown in Fig, 2A. The 
amino acid ratios in acid hydrolysates (6 M HCl, 
1 IO”C, 18 h; the Val-Val bond resisted acid hydrolysis; 
therefore the value for the Val residue was corrected) of 
the peptides obtained were in agreement with the ex- 
pected values (data not shown). 
As reported previously [ 16,171, a synthetic nonapep- 
tide corresponding to the sequence 41-49 of eglin c 
(eglin c (41-49)), which is a binding loop of eglin c with 
subtilisin [4], inhibited cathepsin G and cu-chymo- 
trypsin, of which the enzymatic similarity was previous- 
ly reported 1181, (Ki=4.0~ 10W5 M and 2.0~ lo-’ M, 
respectively) but not leukocyte elastase. Meanwhile, a 
synthetic eglin c (60-63) inhibited leukocyte elastase 
with a Ki value of 1.6 x lo-* M, but not cathepsin G and 
cu-chymotrypsin [ 161. These results indicated that the in- 
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teracting site of eglin c with leukocyte elastase and 
cathepsin G and cr-chymotrypsin might be different, 
although eglin c itself potently inhibited the above three 
enzymes. It is of interest to clarify which part of eglin 
c is required to inhibit the above three enzymes. 
As shown in Fig. 3, eglin c (60-70) inhibited only 
leukocyte elastase, with a Ki value of 1.7 x 10e3 M, 
which is higher than that of eglin c (60-63). Eglin c 
(50-70) and eglin c (45-70) i~ibited leukocyte elastase 
and cu-chymotrypsin but not cathepsin G, implying 
some differences between cathepsin G and cu-chymo- 
trypsin. Eglin c (41-70) could inhibit leukocyte elastase, 
cathepsin G and cu-chymotrypsin (Ki= 1.2 x 10m4 M, 
2.1 x 10e4 M and 7.0x 10m6 M, respectively). Besides 
the reactive site of eglin c, Leu4s-Asp46 [1,4], the pep- 
tide part corresponding to the sequence 41-44 might be 
important for the manifestation of inhibitory activity 
against cathepsin G. This phenomenon is compatible 
with that in the case of eglin c (41-49) [l&17]. 
Ki values for the inhibition of eglin c (41-49) against 
cathepsin G and ~-~h~otr~s~ are 10’-6-times larger 
than those for eglin c [16,17]. In the eglin c molecule, 
Thr44, Asp46 and Arg48 form electrostatic and hydrogen 
bonds with Arg53, Arg” and Gly”, respectively, to 
stabilize the reactive site [4]. However, the eglin c 
(41-49) does not have such electrostatic and hydrogen 
bonds needed to maintain the comfortable and rigid 
conformation necessary for interaction with enzymes. 
This is a possible reason as to why the Ki values of eglin 
c (41-49) are much larger than those of eglin c. The Ki 
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values of eglin c (41-70) for cathepsin G and (Y- 
chymotrypsin are also similar to those of eglin c 
(41-49), indicating that this peptide fragment cannot 
form a proper conformation with electrostatic and 
hydrogen bonds. 
Eglin c (31-70) and eglin c (22-70) inhibited the above 
three enzymes, but the Ki values were similar to those of 
eglin c (41-70). Even in eglin c (22-70), electrostatic and 
hydrogen bonds cannot be formed to maintain a three- 
dimensional structure suitable for interaction with the 
enzymes. 
It is of interest that the synthetic eglin c (8-70) in- 
hibited the above enzymes as potently as ZV-acetyleglin 
c, as shown in Fig. 3, supporting the result of the X-ray 
analysis of the eglin c-subtilisin complex [4]. 
Previously, it was reported that incubation of native 
eglin c with chymotrypsin for 90 min gave three main 
components, inactive complex (molecular mass: about 
30000), native eglin c and a peptide which was iden- 
tified as the C-terminal fragment of eglin c comprising 
position 46-70 [l]. After preincubation of ZV- 
acetyleglin c with a-chymotrypsin or cathepsin G for 90 
min, Ki values towards the above enzymes decreased 
significantly, indicating that a covalent complex formed 
between N-terminal fragment [W-acetyleglin c (l-44)] 
and enzyme was stable. However, in the case of eglin c 
(41-49) with cathepsin G or cu-chymotrypsin, enzyme 
activity regenerated in proportion to the increment of 
preincubation time, suggesting that a covalent complex 
formed was not so stable and hydrolyzed rather soon 
Fig. 2. HPLC of eglin c (8-70) and N*-Ac-eglin c. (A) eglin c (8-70); 
(B) N*-Ac-eglin c; (C) eglin c (8-70) + W-Ac-eglin C. Column, 
YMC-PACK R-C8-5 (4.6 x 250 mm); solvent, A = Hz0 (0.05Vo TFA) 
0 10 20 30 
B = CHsCN (O.OWo TFA) gradient (A/B 80/20 - 20 min+35/65 - 
5 min-*35/65 - 15 min+80/20); flow rate, 1.0 ml/min; absorbance 
Time(min) measurement, 220 nm. 
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Fig. 3. Inhibitory effects of eglin c fragments and W-Ac-eglin c on leukocyte elastase, cathepsin G and cu-chymotrypsin. (A) Leukocyte elastase; 
(B) cathepsin G; (C) cr-chymotrypsin. 
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(unpublished data in our laboratory). From these 
results, it was deduced that eglin c derivatives prepared 
above were also substrates for enzymes, although in the 
short assay used above for determination of Kr values of 
synthetic peptides, the split of the reactive site, Leu45- 
ASHES, was negligible. 
In conclusion, it was suggested that besides the reac- 
tive site in proteinase inhibitor, some amino acid se- 
quences are required to form a three-dimensional struc- 
ture for manifestation of full inhibitory activity by 
means of the increase of the facility of formation of 
enzyme-inhibitor complex and the increase of the 
stability of a covalent complex. 
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